Abraxane’s expected label expansion for treatment of surgically resected pancreatic cancer patients will substantially increase its potential patient population within this indication.
By Louisa Joseph, Analyst
12 April 2016
Celgene is currently investigating Abraxane as an adjuvant therapy in patients with surgically resected metastatic pancreatic adenocarcinoma. As Abraxane is currently only approved in the US and EU for the treatment of metastatic patients, gaining a label expansion into the adjuvant treatment setting would significantly increase its eligible patient population and commercial potential within pancreatic cancer. This approval will depend on the results of the ongoing Phase III APACT study, which is investigating the safety and efficacy of Abraxane and gemcitabine vs gemcitabine monotherapy as adjuvant therapy for patients with resected pancreatic cancer. Assuming positive Phase III results, Datamonitor Healthcare expects Abraxane to be approved for label expansion in Q4 2019 in the US and five major EU markets, and in Q2 2021 in Japan.
Abraxane sales for pancreatic cancer in the US ($m), 2015–2020
Source: Datamonitor Healthcare’s pancreatic cancer forecast, April 2016
This is excerpted from Datamonitor Healthcare’s Pancreatic Cancer: Forecast, covering the future clinical and commercial potential of Abraxane and Tarceva in the pancreatic cancer market, as well as a detailed look at the current pancreatic cancer pipeline.
Get your free demo today – simply fill in the form to the right.